Abstract Number: 1949 • ACR Convergence 2024
Implementation of Pharmacist-Led Comprehensive Medication Management for Puerto Ricans with Rheumatic Diseases
Background/Purpose: Comprehensive Medication Management (CMM) is a standardized intervention provided by clinical pharmacists that uses subjective and objective patient information to create a plan to…Abstract Number: 0376 • ACR Convergence 2024
Preliminary Results of the Ondansetron Pre-medication Trial in Juvenile Idiopathic Arthritis: A Pragmatic Randomized Controlled Trial Nested in the CAPRI Registry
Background/Purpose: About 50% of children with Juvenile Idiopathic Arthritis (JIA) receiving methotrexate (MTX) develop MTX intolerance with severe anticipatory nausea/vomiting and avoidance behaviors. Intolerance often…Abstract Number: 1986 • ACR Convergence 2024
Disease Flare Following Immune Checkpoint Inhibition in Patients with Cancer and Preexisting Vasculitis
Background/Purpose: Immune checkpoint inhibitors (ICI) are effective therapies for patients with cancer, but they often cause immune-related adverse events (irAE). There is limited data on…Abstract Number: 0439 • ACR Convergence 2024
Contraception Counseling and Contraception Use Among SLE and RA/JIA Patients at a Public Medical Center in Los Angeles: Investigating Teratogenic Medication Use and Language Preferences
Background/Purpose: Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)/juvenile idiopathic arthritis (JIA) frequently impact women of reproductive age. Management of these patients is particularly important…Abstract Number: 1997 • ACR Convergence 2024
Features of interleukin-1 and interleukin-6 Inhibitor (IL-1i/IL-6i) Related Severe Delayed Adverse Reactions in Subjects with or Without Reaction-risk Associated HLA-DRB1*15
Background/Purpose: A very serious drug-related adverse event is reported with inhibitors of IL-1 and IL-6 (IL-1i/IL6i). This reaction scores as drug reaction with eosinophilia and…Abstract Number: 0449 • ACR Convergence 2023
Parsing Pathophysiology of Rheumatoid Arthritis-associated Lymphoproliferative Disorders via Whole RNA Transcriptome Analysis: Multi-center Study in Japan
Background/Purpose: Lymphoproliferative disorders (LPD) in rheumatoid arthritis (RA) (RA-LPD) have unique pathophysiological features. More than half of the cases of RA-LPD undergo spontaneous regression after…Abstract Number: 1317 • ACR Convergence 2023
Discontinuation of Biological Disease Modifying Drugs Due to Adverse Drug Reactions in an Inception Rheumatoid Arthritis Cohort
Background/Purpose: There is a well-known risk of developing adverse drug reactions (ADR) in rheumatic patients due, mainly, to the use of Disease Modifying Drugs (DMARD).…Abstract Number: 0462 • ACR Convergence 2023
Breastfeeding Intention in Systemic Lupus Erythematosus Patients
Background/Purpose: Breastfeeding in systemic lupus erythematosus (SLE) has received little attention and the limited data available suggest that women with SLE have lower breastfeeding rates…Abstract Number: 1333 • ACR Convergence 2023
Rheumatoid Arthritis-associated Lymphoproliferative Disorders: A Multi-center Analysis of Clinical Outcomes and Evaluation of Anti-rheumatic Drugs After LPD Onset
Background/Purpose: The largest multi-center collaborative study on lymphoproliferative disorders (LPD) in rheumatoid arthritis (RA) (RA-LPD) in Japan was conducted to characterize its clinical outcomes and…Abstract Number: 0741 • ACR Convergence 2023
Adverse Events Among Patients with and Without Autoimmune Rheumatic Disease Prescribed SGLT2 Inhibitors
Background/Purpose: Sodium glucose cotransporter 2 inhibitors (SGLT2i) are oral hypoglycemic agents for Type II diabetes mellitus (T2D) now prescribed for renal and cardiovascular indications. Patients…Abstract Number: 1362 • ACR Convergence 2023
Improving Reproductive Health Counseling for Pediatric Adolescent Females Prescribed Teratogenic DMARDs
Background/Purpose: Several rheumatologic medications routinely prescribed to adolescent females are teratogenic. However, there is no standard method to educate our patients and their families about…Abstract Number: 1014 • ACR Convergence 2023
Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Therapy and Subsequent Referrals to Rheumatologists at a Private vs Public Medical Center in Los Angeles: Ramifications for Health Disparities
Background/Purpose: Immune checkpoint inhibitors (ICIs) represent a breakthrough in cancer therapies. However, ICIs may be associated with significant immune-related adverse events (irAEs), including rheumatic irAEs.…Abstract Number: 1529 • ACR Convergence 2023
Mycophenolate Mofetil Use in Clinical Practice: Persistence on Therapy and Long-term Adverse Events in a Multicentric Cohort of Scleroderma Patients
Background/Purpose: Mycophenolate mofetil (MMF) is a first-line immunosuppressant treatment for systemic sclerosis (SSc), particularly for patients with interstitial lung disease (ILD) and diffuse skin involvement.…Abstract Number: 1054 • ACR Convergence 2023
Immune Checkpoint Inhibitor Induced Polymyalgia Rheumatica Demonstrates a Similar Scintigraphic Appearance to Classical Polymyalgia Rheumatica on 18F-Fluorodeoxyglucose PET/CT
Background/Purpose: Of the rheumatic immune-related adverse events that follow immune checkpoint inhibitor (ICI) cancer immunotherapy, de novo PMR-like episodes without inflammatory arthritis (ICI-PMR) appear to…Abstract Number: 1919 • ACR Convergence 2023
Arthroplasty Outcomes in Immune Checkpoint Inhibitor-Treated Patients: A Single Center Series
Background/Purpose: Immune checkpoint inhibitors (ICI) have changed the landscape of cancer treatment dramatically, but because of their mechanism of action they are also known to…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 10
- Next Page »